[go: up one dir, main page]

NO20090459L - 18-metyl-19-nor-androst-4-en-17,17-spiroeter (18-metyl-19-nor-20-spiroks-4-en-3-on) og farmasoytiske preparater inneholdende disse - Google Patents

18-metyl-19-nor-androst-4-en-17,17-spiroeter (18-metyl-19-nor-20-spiroks-4-en-3-on) og farmasoytiske preparater inneholdende disse

Info

Publication number
NO20090459L
NO20090459L NO20090459A NO20090459A NO20090459L NO 20090459 L NO20090459 L NO 20090459L NO 20090459 A NO20090459 A NO 20090459A NO 20090459 A NO20090459 A NO 20090459A NO 20090459 L NO20090459 L NO 20090459L
Authority
NO
Norway
Prior art keywords
methyl
ene
spirox
androst
pharmaceutical compositions
Prior art date
Application number
NO20090459A
Other languages
English (en)
Inventor
Rolf Bohlmann
Hans-Peter Muhn
Norbert Gallus
Katja Prelle
Jan Huebner
Tidl Kurz Steffen Borden
Joachim Kuhnke
Frederik Menges
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38626491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090459(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of NO20090459L publication Critical patent/NO20090459L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Oppfinnelsen angår nye 18-metyl-19-norandrost-4-en-17,17-spiroetere av generell formel (I), hvor Z = 0, to H, =N0R eller =NNHS02R, R = H eller rettkjedet eller forgrenet Ci_4 eller C3_4alkyl, R4 = H, halogen eller CF3 og R6 og/eller R7 er i a- eller p-still-ing og R6 og R7 uavhengig = H eller rettkjedet eller forgrenet C1-4 eller C3_4alkyl eller et rettkjedet eller forgrenet C2~4 eller C3-4alkylen eller et mettet C3_5sykloalkyl, eller sammen danner en metylengruppe eller en dobbelt-binding. De nye forbindelser har gestagen eller antimineralkortikoid virkning.
NO20090459A 2006-06-29 2009-01-28 18-metyl-19-nor-androst-4-en-17,17-spiroeter (18-metyl-19-nor-20-spiroks-4-en-3-on) og farmasoytiske preparater inneholdende disse NO20090459L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006030416A DE102006030416A1 (de) 2006-06-29 2006-06-29 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
PCT/EP2007/005893 WO2008000521A1 (de) 2006-06-29 2007-06-29 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate

Publications (1)

Publication Number Publication Date
NO20090459L true NO20090459L (no) 2009-03-10

Family

ID=38626491

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090459A NO20090459L (no) 2006-06-29 2009-01-28 18-metyl-19-nor-androst-4-en-17,17-spiroeter (18-metyl-19-nor-20-spiroks-4-en-3-on) og farmasoytiske preparater inneholdende disse

Country Status (40)

Country Link
US (1) US7846917B2 (no)
EP (1) EP2038294B1 (no)
JP (1) JP5326085B2 (no)
KR (1) KR101440640B1 (no)
CN (1) CN101511857B (no)
AR (1) AR061736A1 (no)
AT (1) ATE490967T1 (no)
AU (1) AU2007263944B2 (no)
BR (1) BRPI0713934A2 (no)
CA (1) CA2656443C (no)
CL (1) CL2007001919A1 (no)
CO (1) CO6150134A2 (no)
CR (1) CR10548A (no)
CY (1) CY1111658T1 (no)
DE (2) DE102006030416A1 (no)
DK (1) DK2038294T3 (no)
DO (1) DOP2008000089A (no)
EC (1) ECSP089014A (no)
ES (1) ES2357698T3 (no)
GT (1) GT200800307A (no)
HN (1) HN2008001934A (no)
HR (1) HRP20110161T1 (no)
IL (1) IL195935A0 (no)
MA (1) MA30596B1 (no)
MX (1) MX2009000082A (no)
MY (1) MY155015A (no)
NO (1) NO20090459L (no)
NZ (1) NZ573951A (no)
PE (1) PE20080995A1 (no)
PL (1) PL2038294T3 (no)
PT (1) PT2038294E (no)
RS (1) RS51722B (no)
RU (1) RU2440365C2 (no)
SI (1) SI2038294T1 (no)
TN (1) TNSN08518A1 (no)
TW (1) TWI413645B (no)
UA (1) UA94952C2 (no)
UY (1) UY30451A1 (no)
WO (1) WO2008000521A1 (no)
ZA (1) ZA200900673B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007063498A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063496A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102008026793A1 (de) 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (zh) 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
WO2013160200A1 (de) * 2012-04-23 2013-10-31 Bayer Pharma Aktiengesellschaft ANWENDUNG VON 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONEN BEI DER THERAPIE DER MENORRHAGIA, SOWIE 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONE ENTHALTENDE INTRAUTERINE SYSTEME FÜR DIE THERAPIE UTERINEN BLUTUNGSSTÖRUNGEN
WO2015055789A1 (en) * 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION
KR20160072114A (ko) * 2013-10-18 2016-06-22 베이어 오와이 자궁내 전달 시스템
CN105237605B (zh) * 2014-07-11 2019-01-25 上海迪赛诺生物医药有限公司 一种用于合成孕二烯酮的中间体及其制备方法和应用
CN109575094B (zh) * 2019-01-17 2021-01-26 浙江仙琚制药股份有限公司 替勃龙中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798213A (en) * 1971-01-25 1974-03-19 Merck & Co Inc 7 alpha-methyl-20-spiroxane-3-ones and process
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3111950A1 (de) 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15(beta).16(beta)-methylen-4-androsten-3-one, verfahren zu ihrer herstellung und verwendung als arzneimittel
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
EP1223174A3 (en) 1996-12-11 2005-03-16 G.D. Searle & Co. Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
AU2007263944B2 (en) 2013-07-18
US20080153787A1 (en) 2008-06-26
EP2038294B1 (de) 2010-12-08
CL2007001919A1 (es) 2008-05-16
CN101511857B (zh) 2012-10-31
IL195935A0 (en) 2009-09-01
MX2009000082A (es) 2009-01-23
BRPI0713934A2 (pt) 2012-12-04
TWI413645B (zh) 2013-11-01
AR061736A1 (es) 2008-09-17
MY155015A (en) 2015-08-28
ZA200900673B (en) 2010-04-28
TNSN08518A1 (en) 2010-04-14
CA2656443A1 (en) 2008-01-03
PT2038294E (pt) 2011-03-14
RU2440365C2 (ru) 2012-01-20
EP2038294A1 (de) 2009-03-25
RS51722B (sr) 2011-10-31
RU2009102772A (ru) 2010-08-10
ES2357698T3 (es) 2011-04-28
KR101440640B1 (ko) 2014-09-22
HN2008001934A (es) 2012-01-17
CA2656443C (en) 2014-10-07
JP2009541405A (ja) 2009-11-26
GT200800307A (es) 2009-11-03
UY30451A1 (es) 2008-01-31
JP5326085B2 (ja) 2013-10-30
NZ573951A (en) 2011-06-30
PL2038294T3 (pl) 2011-05-31
HRP20110161T1 (hr) 2011-04-30
SI2038294T1 (sl) 2011-04-29
DE502007005902D1 (de) 2011-01-20
DE102006030416A1 (de) 2008-01-03
TW200811193A (en) 2008-03-01
CR10548A (es) 2009-01-27
WO2008000521A1 (de) 2008-01-03
AU2007263944A1 (en) 2008-01-03
CN101511857A (zh) 2009-08-19
ECSP089014A (es) 2009-01-30
DK2038294T3 (da) 2011-03-28
PE20080995A1 (es) 2008-10-03
DOP2008000089A (es) 2009-02-15
HK1133659A1 (en) 2010-04-01
KR20090021294A (ko) 2009-03-02
CY1111658T1 (el) 2015-10-07
MA30596B1 (fr) 2009-07-01
US7846917B2 (en) 2010-12-07
ATE490967T1 (de) 2010-12-15
UA94952C2 (uk) 2011-06-25
CO6150134A2 (es) 2010-04-20

Similar Documents

Publication Publication Date Title
NO20090459L (no) 18-metyl-19-nor-androst-4-en-17,17-spiroeter (18-metyl-19-nor-20-spiroks-4-en-3-on) og farmasoytiske preparater inneholdende disse
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
ECSP088975A (es) Nuevos análagos de piridina
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
DE602006013493D1 (de) Oxadiazolylpyrazolopyrimidine als mglur2-antagonisten
NO20083919L (no) Pyridin- og pyrimidinderivater som mGluR2-antagonister
GEP20146125B (en) Aminopyrimidines as syk inhibitors
HRP20070076A2 (en) Pyrimidine derivatives
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
MX2009008925A (es) Compuestos de la formula (i) como inhibidores de proteasa de serina.
DE602005016297D1 (de) Antithrombotische diamide
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
UY29325A1 (es) Nuevos derivados de 2 - amino-piridina
NO20085317L (no) Imidazoazepinonforbindelser
UY30865A1 (es) Nuevos analogos de piridina x 161
TW200833335A (en) New pyridine analogues
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
UY30868A1 (es) Nuevos compuestos de piridina, composiciones farmacéuticas conteniéndolas y aplicaciones.
ECSP10010710A (es) Nuevas carboxamidas heterociclicas para su uso como inhibidores de trombina
MX2009009345A (es) Compuestos de pirimidinona fusionados como ligandos de mglur.
DE602006017724D1 (de) Salicylsäurederivate
UY30867A1 (es) Nuevos analogos de piridina vii 543
ATE550326T1 (de) Als modulatoren von hdl einsetzbare verbindungen

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

FC2A Withdrawal, rejection or dismissal of laid open patent application